HOOKIPA Pharma (HOOK) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with the Chairman and Corporate Secretary present, and was held virtually to enhance accessibility for shareholders worldwide.
The agenda and meeting materials were made available through the virtual portal, and directors, officers, auditors, and counsel were introduced.
The sequence of business included opening polls, presenting proposals, Q&A, and closing polls.
Board and executive committee updates
Directors and officers, including the CEO, CFO, CSO, COO, and CDO, were introduced, along with independent auditors and outside counsel.
Shareholder proposals
Four proposals were presented: election of two Class II directors, ratification of the independent auditor, increase in authorized shares, and authorization for a reverse stock split.
No advance notice of alternative director nominations was received.
Latest events from HOOKIPA Pharma
- HB-200 plus pembrolizumab delivers high response rates and durable outcomes in HPV16+ head and neck cancer.HOOK
Status Update31 Jan 2026 - HB-200 shows robust efficacy and is on track for pivotal trials, aiming for 2027 approval.HOOK
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Arenavirus immunotherapy platform advances with strong efficacy in HPV16+ and KRAS-mutant cancers.HOOK
Study Update Presentation27 Jun 2025 - Clinical progress and cost cuts offset by ongoing going concern risk and cash decline.HOOK
Q3 202413 Jun 2025 - Positive clinical progress and restructuring amid ongoing financial risk.HOOK
Q2 202413 Jun 2025